Cantor Fitzgerald Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $24.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price cut by Cantor Fitzgerald from $29.00 to $24.00 in a research note released on Thursday, MarketBeat reports. They currently have an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Zevra Therapeutics’ FY2026 earnings at $0.43 EPS.

ZVRA has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 20th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. JMP Securities reduced their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 13th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Finally, Zacks Research downgraded Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $22.80.

Zevra Therapeutics Stock Down 3.1%

Zevra Therapeutics stock opened at $8.81 on Thursday. The stock has a 50 day moving average of $9.56 and a two-hundred day moving average of $9.56. Zevra Therapeutics has a twelve month low of $6.19 and a twelve month high of $13.16. The stock has a market capitalization of $494.55 million, a price-to-earnings ratio of -41.95 and a beta of 1.52. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.The business had revenue of $26.06 million during the quarter, compared to analysts’ expectations of $26.64 million. As a group, research analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode purchased 5,000 shares of Zevra Therapeutics stock in a transaction on Tuesday, August 19th. The shares were bought at an average price of $9.16 per share, with a total value of $45,800.00. Following the completion of the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $412,200. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the completion of the sale, the chief executive officer owned 222,016 shares in the company, valued at $2,402,213.12. This represents a 8.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP grew its position in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after purchasing an additional 740,584 shares during the period. AIGH Capital Management LLC boosted its stake in Zevra Therapeutics by 82.4% in the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after buying an additional 649,495 shares during the last quarter. Readystate Asset Management LP boosted its stake in Zevra Therapeutics by 924.6% in the 1st quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock worth $5,116,000 after buying an additional 616,370 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after buying an additional 550,000 shares during the period. Finally, Woodline Partners LP increased its stake in shares of Zevra Therapeutics by 11.5% during the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock valued at $34,571,000 after acquiring an additional 476,032 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.